Skip to main content

Hypothalamic Obesity

Metabolic Diseases
1
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
5100%
+ 3 programs with unclassified modality

Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.

$70.5B marketMature↑ Growing30 products15 companies

Key Trends

  • GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
  • SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
  • Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins

Career Verdict

Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch14.5yr
#2OZEMPICGrowing
$9.2B
Novo Nordisk·Peak11.9yr
#3JARDIANCEGrowing
$8.8B
#5FARXIGAGrowing
$4.3B
AstraZeneca·Peak14.9yr

Drug Class Breakdown

FXa Inhibitors (Anticoagulants)
$18.3B(26%)

stable, mature franchise

GLP-1 Agonists
$18.2B(26%)

rapid growth, expanding indications

SGLT2 Inhibitors
$9.4B(13%)

growing, cardio-renal expansion

Insulin Analogs
$7.8B(11%)

stable, generics pressure

DPP-4 Inhibitors
$5.4B(8%)

declining, patent cliff 2027

Career Outlook

Growing

Metabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.

Breaking In

Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.

For Experienced Professionals

Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.

In-Demand Skills

Commercial acumen and healthcare economics (GLP-1 market dynamics)Regulatory affairs (label expansion, indication creep for SGLT2/GLP-1)Digital health and CGM/insulin device experienceReal-world evidence generation and health outcomes research

Best For

Brand Manager (peak-cycle GLP-1 products)Medical Science Liaison (cardio-renal expansion)Market Access / Health Economics (SGLT2 outcomes)Commercial Operations (launch support for next-gen)

Hiring Landscape

$153K-$274K

Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.

574
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

270Growing
154Growing
42Stable
38Stable

By Department

Commercial(29%)
$220K
Engineering(22%)
$197K
Manufacturing(8%)
$274K
Clinical Operations(4%)
$153K

Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
OctreotidePhase 4Peptide
Rhythm Pharmaceuticals
6 programs
Part A: RM-718 or placeboPHASE_1_21 trial
BivamelagonPHASE_21 trial
LB54640PHASE_21 trial
SetmelanotidePHASE_2Peptide1 trial
SetmelanotidePHASE_3Peptide1 trial
+1 more programs
Active Trials
NCT06239116Active Not Recruiting111Est. Nov 2028
NCT07156578Enrolling By Invitation25Est. Apr 2028
NCT06046443Completed28Est. Feb 2026
+3 more trials
Novartis
NovartisBASEL, Switzerland
1 program
OctreotidePHASE_4Peptide1 trial
Active Trials
NCT00171613Completed32

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
NovartisOctreotide
Rhythm PharmaceuticalsSetmelanotide
Rhythm PharmaceuticalsSetmelanotide
Rhythm PharmaceuticalsBivamelagon
Rhythm PharmaceuticalsLB54640
Rhythm PharmaceuticalsSetmelanotide
Rhythm PharmaceuticalsPart A: RM-718 or placebo

Clinical Trials (7)

Total enrollment: 396 patients across 7 trials

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

Start: Feb 200532 patients
Phase 4Completed

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Start: Sep 2025Est. completion: Mar 202839 patients
Phase 3Recruiting

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Start: Apr 2023Est. completion: Apr 2027143 patients
Phase 3Active Not Recruiting

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

Start: Nov 2025Est. completion: Apr 202825 patients
Phase 2Enrolling By Invitation

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Start: Jul 2024Est. completion: Feb 202628 patients
Phase 2Completed

Open-Label Study of Setmelanotide in Hypothalamic Obesity

Start: Jun 2021Est. completion: Jun 202218 patients
Phase 2Completed
NCT06239116Rhythm PharmaceuticalsPart A: RM-718 or placebo

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Start: Mar 2024Est. completion: Nov 2028111 patients
Phase 1/2Active Not Recruiting

Related Jobs in Metabolic Diseases

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 396 patients
Peptide is the dominant modality (100% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.